Mesoblast announces board changes as two directors retire
Mesoblast says William Burns and Philip Krause will leave its board, while Jane Bell takes over the nomination and remuneration committee.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Mesoblast Limited announced through GlobeNewswire rotational changes to its board and the retirement of some directors. William Burns, who has served on the board since 2014, will step down at the 2026 Annual General Meeting. Dr Philip Krause, a director since 2022, will also retire.
Jane Bell AM will become chair of the Nomination and Remuneration Committee, having co-chaired it with Burns since April 2026. The company also plans to appoint new directors with U.S. and global commercial experience in biotechnology and pharmaceuticals.
Chair Philip Facchina said Mesoblast is now a revenue-generating commercial company following the launch of RYONCIL in the United States.
why it matters
Board changes rarely move a stock on their own. The bigger signal is the focus on commercial expertise, which may point to a shift from drug development toward sales and growth.
market impact
Mesoblast shares: board changes with limited market impact
tags
instruments
sources
- Mesoblast Board Changes — globenewswire.com, 1 November 2026 at 23:46 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗